BDTX Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 5.7%, SMA50 -0.31%, SMA200 -14.58%). The stock’s 14-day RSI is 53.12 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.39% below its high and over 109.21% above its low. Average 10-day trading volume of 541.62 thousand shares is below the 3-month average of 1.07 million, indicating normal recent market interest.

Black Diamond Therapeutics, Inc. has 56.94 million shares outstanding. The public float is 39.24 million shares, elevated short interest at 15.97% of float. This equals 6.33 million shares. The short ratio is 6.16 days. Institutional investors hold 79.32% of the float. Insiders own 0.63%. Behbahani Ali holds 4.45 million shares, BB BIOTECH AG has 4.44 million shares and Versant Venture Capital VI, L.P. has 3.73 million shares.

Black Diamond Therapeutics, Inc. generated EPS of $0.36 over the past year. Five-year average earnings growth is -5.22%. Wall Street analysts project EPS growth of 11.38% annually over the next five years. The latest quarter delivered EPS of -$0.15. The next quarter is forecast at -$0.18. Next year's EPS is expected at -$5.14. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $8.00. The high target offers 500.0% upside. The low target suggests 220.0% downside. The mean target is $10.12. This offers 304.8% upside. Black Diamond Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by -31.82%. The prior quarter beat by -31.82%. Over the last six quarters, Apple has recorded several small beats. These include -25.59% in November 05, 2024.

Black Diamond Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.26. This means the shares are trading above this model’s fair value.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) closed at $2.50 USD, losing -$0.09 (-3.47%) from the previous close of $2.59. The stock is currently mid-range between its 52-week high and low $1.20 and $4.94. With a market capitalization of about $142.44 million, Black Diamond Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.36). Key stats such as the average daily volume over the past year has been around 1.08 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Black Diamond Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mark A. Velleca, the company employs approximately 24 people and listed since January 31, 2020. Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) shares are flat -1.23% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Black Diamond Therapeutics, Inc. trading at a premium to the broader market with a P/E of 6.69. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $16.62, suggesting 564.8% upside. Our AI forecast model points to short-term strength (1.6% over two weeks), a medium-term fall (-26.0% over three months), and a longer-term gain (459.6% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Black Diamond Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.6%, with price expected at $2.54 by March 12, 2026, within a range of $2.41 to $2.67 3-Month Outlook: Projected fall of -26.0%, reaching $1.85 by May 27, 2026, with a range of $1.60 to $2.02. 1-Year Outlook: Projected gain of 459.6%, with price at $13.99 by February 26, 2027, within a range of $4.26 to $21.59.

Black Diamond Therapeutics, Inc. trades at a P/E ratio of 6.69, slightly below the S&P 500 average, with a price-to-sales ratio of 2.07 and a price-to-book ratio of 1.14 suggesting the stock is closer to book value. The P/FCF stands at 6.78, also below market averages.